H. Tateyama et al., Immunoreactivity of a new CD5 antibody with normal epithelium and malignant tumors including thymic carcinoma, AM J CLIN P, 111(2), 1999, pp. 235-240
Citations number
29
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Medical Research Diagnosis & Treatment
CD5, first recognized on subsets of lymphocytes, also is detected in thymic
carcinoma but not in thymoma or other malignant tumors. We studied CD5 exp
ression in 73 cases of malignant tumors of various organs, 22 cases of thym
oma, and 7 cases of thymic carcinoma by immunohistochemistry using the new
monoclonal anti-CD5 antibody, NCL-CD5-4C7, with a pressure cooker antigen r
etrieval method. All cases of thymic carcinoma showed positive staining for
CD5, predominantly on the cell membrane. Two of 4 cases of atypical thymom
a also showed focal positivity, whereas the other types of thymoma were neg
ative. CD5 was detected in cases of malignant turners other than squamous c
ell carcinoma and in the normal epithelium of their counterparts. Squamous
cell carcinomas of various organs were negative for CD5. Malignant mesothel
ioma showed peculiar intracytoplasmic staining in contrast to the other tum
ors. The NCL-CD5-4C7 positivity in thymic epithelial tumors may support the
hypothesis suggesting progression of atypical thymoma to thymic carcinoma.
NCL-CD5-4C7 may be useful in the differential diagnosis of mediastinal tum
ors, especially between thymic carcinoma and metastatic squamous cell carci
noma of various primary sites, and for distinguishing malignant mesotheliom
a from adenocarcinoma of the lung by the different staining pattern.